Observational studyBMC cancer2025

Comparison of outcomes with elranatamab and real world treatments in the UK for triple class exposed relapsed and refractory multiple myeloma.

Carmen Tsang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.